(Q51656832)

9 April 2018

title

Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML. (English)

1 reference

9 April 2018

author name string

Joerg U Schmohl

1

1 reference

9 April 2018

Tina Nuebling

2

1 reference

9 April 2018

Julia Wild

3

1 reference

9 April 2018

Tanja Kroell

4

1 reference

9 April 2018

Lothar Kanz

5

1 reference

9 April 2018

Helmut R Salih

6

1 reference

9 April 2018

Helga Schmetzer

7

1 reference

9 April 2018

publication date

7 July 2016

1 reference

9 April 2018

Journal of Investigative Medicine

published in

1 reference

9 April 2018

volume

64

1 reference

9 April 2018

issue

8

1 reference

9 April 2018

page(s)

1252-1260

1 reference

9 April 2018

Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

4-1BB as a therapeutic target for human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

In vivo 4-1BB deficiency in myeloid cells enhances peripheral T cell proliferation by increasing IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

The erythroid leukemias: a comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Cutting edge: Expression of functional CD137 receptor by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

21 January 2018

The B7-CD28 superfamily

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Expression of the co-stimulatory molecule B7 on melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJIM-2016-000081

21 January 2018

Identifiers

DOI

10.1136/JIM-2016-000081

1 reference

9 April 2018

PubMed ID

27388616

1 reference

9 April 2018